newsfilter
← Latest News
GlobeNewswire·

VBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committee to Continue Study as Planned

Phase 3 OVAL trial enrolled 409 patients globally at centers in the United States, Europe, Israel, and Japan Top-line data from progression free survival (PFS) primary endpoint expected in 2H 2022 expected to have the potential to support a Biologics L